Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback.
OBJECTIVE
To test three theories of hypercortisolemia in depression-hypothalamic overdrive, impaired glucocorticoid feedback, or autonomous cortisol production.


METHODS
We applied an overnight low-cortisol feedback strategy by administering metyrapone to hypercortisolemic depressed in-patients and control subjects.


RESULTS
Under metyrapone, the increases of plasma adrenocorticotropic hormone (ACTH) concentrations and of basal and pulsatile ACTH secretion were not exaggerated in hypercortisolemic depressed patients compared with control subjects. ACTH approximate entropy (ApEn) did not differ at baseline or under metyrapone. Thus, neither hypothalamic overdrive nor irregular ACTH secretion was seen. We did not detect impaired cortisol feedback: the ACTH response was not reduced, and ApEn measures that are sensitive to feedback changes were comparable in both groups. Metyrapone disrupted cortisol secretory regularity in depressed and control subjects. On the baseline day, basal cortisol secretion was significantly increased and was highly irregular (high ApEn), and ACTH-cortisol cross-ApEn was markedly elevated in high-cortisol patients.


CONCLUSIONS
Classical feed-forward overdrive and impaired feedback theories of hypercortisolemia in depression were not supported. Depressive hypercortisolemia may result from alternative pathophysiological mechanisms involving irregular basal hypersecretion of cortisol, associated with adrenal enlargement, possibly through splanchnic sympathetic activation of the adrenal cortex.
Pacific Behavioral Research Foundation, Carmel, CA, USA.
B J
BJ
Carroll
A
A
Iranmanesh
D M
DM
Keenan
F
F
Cassidy
W H
WH
Wilson
J D
JD
Veldhuis
D000324:Adrenocorticotropic Hormone / Q000097:blood* / Q000378:metabolism; D000328:Adult; D016022:Case-Control Studies; D003480:Cushing Syndrome / Q000150:complications / Q000503:physiopathology*; D003865:Major Depressive Disorder / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D004791:Enzyme Inhibitors; D025461:Feedback, Physiological; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D006854:Hydrocortisone / Q000097:blood* / Q000378:metabolism; D008297:Male; D008797:Metyrapone; D008875:Middle Aged; D010913:Pituitary-Adrenal System / Q000378:metabolism / Q000503:physiopathology*
D004791:Enzyme Inhibitors; D005938:Glucocorticoids; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone; D008797:Metyrapone